EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 3.0

Prospective Dose-Finding of Esketamine for Suppressing Cervical Dilation Response in Ambulatory Hysteroscopy Under Monitored Anesthesia Care

Lijuan Yan iD, Xiao Wang iD, Jianfei Wei, Meiqin Zhang, Bin Yang iD

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s557340 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Lijuan Yan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of…. Hauptthemen laut MEDLINE: Anesthesia, Hysteroscopy, Ketamine. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cervical dilation during ambulatory hysteroscopy often triggers somatic responses that challenge patient comfort and procedure smoothness. While esketamine's unique analgesic profile could address this, its effective dose within a dexmedetomidine-remifentanil monitored anesthesia care (MAC) protocol is undefined.

Methods

In this prospective, double-blind, dose-finding study, 30 women received a standardized MAC protocol (dexmedetomidine 0.6 μg∙kg-1 loading dose followed by 0.4 μg∙kg-1∙h-1, with remifentanil 5 μg∙kg-1∙h-1). Esketamine was administered via Dixon's up-and-down sequential design (initial dose 0.3 mg∙kg-1; increments/decrements 0.02 mg∙kg-1) before cervical dilation. Positive response is defined as the absence of purposeful movement. The median effective dose (ED50) and 95% effective dose (ED95) were calculated using probit regression.

Results

30 patients completed the study. The ED50 of esketamine was 0.36 mg∙kg-1 (95% CI 0.35-0.37) and the ED95 was 0.39 mg∙kg-1 (95% CI 0.37-0.42). Hemodynamic stability was maintained (mean arterial pressure change ≤15% from baseline) with no respiratory depression. Adverse events were self-limiting dizziness (66.7%) and nausea (6.7%). Recovery was swift, with a time to meet post-anesthesia care unit (PACU) discharge criteria of 17.93±3.30 min, and patient satisfaction was high (median score 9/10, IQR 8-10).

Conclusion

Under dexmedetomidine-remifentanil MAC, esketamine 0.39 mg∙kg-1 (ED95) effectively suppresses the cervical dilation response, promotes hemodynamic and respiratory stability, and facilitates a rapid, enhanced recovery after surgery (ERAS)-compliant recovery. This dose-finding study provides a practical and effective anesthetic combination for clinical implementation in ambulatory hysteroscopy. Clinical Trial Registration: ClinicalTrials.gov (identifier: NCT07034963). Principal Investigator: Lijuan Yan. This study determined the optimal dose of esketamine by testing different doses in thirty patients, finding that 0.39 mg∙kg−1 effectively prevented patient movement and discomfort during cervical dilation in ambulatory hysteroscopy. Patients showed minimal movement during cervical dilation, while blood pressure and heart rate remained stable. Notably, no episodes of respiratory depression occurred. The most common side effect was temporary, mild dizziness, which resolved quickly without treatment. Importantly, patients recovered within about 20 minutes. This allowed for same-day discharge and was associated with high satisfaction with their care. This study provides anesthesiologists with robust, evidence-based guidance for using esketamine to enhance patient comfort and streamline recovery in ambulatory settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnesthesiaHysteroscopyKetamineAdultFemaleHumansMiddle AgedDexmedetomidineDose-Response Relationship, DrugDouble-Blind MethodProspective StudiesRemifentanil

Stichwörter der Autor:innen

cervical dilation responseeffective doseesketaminehysteroscopymonitored anesthesia care

Substanzen

DexmedetomidineEsketamineKetamineRemifentanil

Autor:innen und Institutionen

  • Department of Anesthesiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
  • Department of Ultrasound, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, People's Republic of China.
  • Department of Anesthesiology, The First Hospital of Zhangzhou China Merchants Economic and Technological Development Zone, Zhangzhou, People's Republic of China.
  • Department of Medical Affairs, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
  • Xiamen Daytime Medical Management Quality Control Center, Xiamen, People's Republic of China.

ORCID-Profile: Lijuan Yan, Xiao Wang, Bin Yang

Zitieren

APA

Yan, L., Wang, X., Wei, J., Zhang, M., & Yang, B. (2025). Prospective Dose-Finding of Esketamine for Suppressing Cervical Dilation Response in Ambulatory Hysteroscopy Under Monitored Anesthesia Care. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s557340

Vancouver

Yan L, Wang X, Wei J, Zhang M, Yang B. Prospective Dose-Finding of Esketamine for Suppressing Cervical Dilation Response in Ambulatory Hysteroscopy Under Monitored Anesthesia Care. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s557340

BibTeX
@article{Yan2025,
  author = {Yan, Lijuan and Wang, Xiao and Wei, Jianfei and Zhang, Meiqin and Yang, Bin},
  title = {Prospective Dose-Finding of Esketamine for Suppressing Cervical Dilation Response in Ambulatory Hysteroscopy Under Monitored Anesthesia Care},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s557340}
}
Kostenlos starten →